Jiang et al. [162] investigated the drug resistance model of the 4T1 mouse triple-negative breast cancer (TNBC) cell line and determined that TYRO3 has a significant correlation to the resistance of cancer patients to anti-PD-1/PD-L1 treatments. Here, TYRO3 is linked to triple-negative breast carcinoma.